Cite
MLA Citation
Ravit Geva et al.. “First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.” Cancer, vol. 126, no. 22, 2020, pp. 4926–4935. http://access.bl.uk/ark:/81055/vdc_100113081099.0x000063